title: [Treatment outcomes with paclitaxel for advanced gastric cancer patients previously treated with TS-1].
abstract: In the present report, we describe the treatment results of paclitaxel in patients with metastatic gastric cancer previously treated with TS-1 or combination chemotherapy of TS-1 and CDDP. Paclitaxel was administered to 4 patients at a weekly dose of 80 mg/m2/day for three weeks followed by a one week interval. Remarkable tumor reduction was observed in 2 patients. Case 1: A 52-year-old male patient with gastric cancer and multiple liver metastases was treated by weekly infusion of paclitaxel as a 2nd line chemotherapy. After 1 course, the tumor was remarkably reduced, and the reduction was judged PR. Case 2: A 31-year-old male patient presented with lymphoangitis carcinomatosa and obstructive jaundice resulting from cancerous lymphoadenopathy. After 1 course, chest radiographs and abdominal CT scan showed remarkable reduction of these lesions. The adverse effects observed with this drug were leucocytopenia and liver dysfunction, both of which improved soon. These results indicate paclitaxel is effective for advanced gastric cancer pretreated with TS-1.
authors.affiliation: Dept. of Gastroenterology, Sendai National Hospital.
authors.forename: Tatsuhiko
authors.initials: T
authors.lastname: Suzuki
authors.forename: Masahiro
authors.initials: M
authors.lastname: Iwabuchi
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Matsuda
authors.forename: Gou
authors.initials: G
authors.lastname: Imai
authors.forename: Hirosh
authors.initials: H
authors.lastname: Yokoyama
authors.forename: Atsuhiro
authors.initials: A
authors.lastname: Mochida
authors.forename: Hiroki
authors.initials: H
authors.lastname: Takahashi
authors.forename: Masaaki
authors.initials: M
authors.lastname: Shiina
authors.forename: Koudou
authors.initials: K
authors.lastname: Yamada
authors.forename: Jyunichi
authors.initials: J
authors.lastname: Ishibashi
authors.forename: Shinichi
authors.initials: S
authors.lastname: Suzuki
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Chida
authors.forename: Keiichi
authors.initials: K
authors.lastname: Tadokoro
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018279:Carcinoma, Signet Ring Cell / Q000188:drug therapy* / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004338:Drug Combinations; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage; D017239:Paclitaxel / Q000008:administration & dosage*; D011725:Pyridines / Q000008:administration & dosage; D012074:Remission Induction; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005641:Tegafur / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D004338:Drug Combinations; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D017239:Paclitaxel; D002945:Cisplatin